Junshi biological completed the rolling submission of the listing application of treprizumab for nasopharyngeal carcinoma to the FDA
On September 1, Junshi biological announced that the company had completed the rolling submission of the biological product license application (BLA) for treprizumab combined with gemcitabine / cisplatin as the first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma, and single drug for the second-line and above treatment after platinum containing chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.
This text is a result of machine translation.
Related companies：
Briefing May 24, 2022 02:24 PM
· Healthcare
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Briefing May 21, 2022 06:44 AM
· Financials
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
May 11, 2023 05:07 PM
Jan 06, 2023 08:30 AM
Briefing Apr 18, 2022 10:18 PM
· Technology
A number of enterprises on the science and innovation board are listed on the "white list" of key enterprises for operation guarantee and transfer
Healthcare
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Briefing Feb 07, 2022 06:49 PM
· Healthcare
Fengtai District of Beijing will lift the epidemic prevention zone of the whole region from now on.
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Yesterday 02:21 PM
Insight
In-depth